Home › Funds › M28 Capital Management LP › SLN
M28 Capital Management LP position in SLN
SILENCE THERAPEUTICS PLC · Health Care
M28 Capital Management LP reported holding 101,203 shares of SLN (SILENCE THERAPEUTICS PLC) in its Q3 2026 13F filing — a position valued at US$1.1M, representing 3.07% of its reported portfolio and ranking #5 among its reported holdings. M28 Capital Management LP has disclosed SLN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How M28 Capital Management LP's SLN position evolved
M28 Capital Management LP first disclosed a stake in SLN in Q3 2023 at 363,800 shares (US$3.6M). The position peaked in Q1 2024 at 299,400 shares, worth US$6.5M. Across 13 filings, M28 Capital Management LP increased the stake 0 time(s), trimmed it 3 time(s) and left it unchanged 9 time(s). The most recent filing (Q3 2026) shows 101,203 shares valued at US$1.1M. Notable position changes include a 38% trim in Q2 2024 (shares fell 4% over the following quarter), a 45% trim in Q1 2026 (shares rose 108% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 363.80K | $3.57M | New |
| Q4 2023 | 363.80K | $6.32M | Hold |
| Q1 2024 | 299.40K | $6.47M | Reduce |
| Q2 2024 | 185.10K | $3.52M | Reduce |
| Q3 2024 | 185.10K | $3.37M | Hold |
| Q4 2024 | 185.10K | $1.27M | Hold |
| Q1 2025 | 185.10K | $521.98K | Hold |
| Q2 2025 | 185.10K | $1.07M | Hold |
| Q3 2025 | 185.10K | $960.67K | Hold |
| Q4 2025 | 185.10K | $1.13M | Hold |
| Q1 2026 | 101.20K | $533.34K | Reduce |
| Q2 2026 | 101.20K | $1.11M | Hold |
| Q3 2026 | 101.20K | $1.11M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About SLN and 13F data
SLN (SILENCE THERAPEUTICS PLC) is a Health Care company. 37 other funds we track also report a position in SLN — the largest reported positions include TCG Crossover Management, LLC (US$33.3M), Siren, L.L.C. (US$31.6M), Redmile Group, LLC (US$23.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding SLN
- TCG Crossover Management, LLC 3.03M sh · $33.31M · Q2 2026
- Siren, L.L.C. 2.89M sh · $31.56M · Q3 2026
- Redmile Group, LLC 2.16M sh · $23.77M · Q2 2026
- Nextech Invest Ltd. 952.40K sh · $10.46M · Q2 2026
- 5AM Venture Management, LLC 476.20K sh · $5.23M · Q2 2026
- GREAT POINT PARTNERS LLC 450.00K sh · $4.94M · Q2 2026
- Tetragon Partners GP Ltd 300.00K sh · $3.29M · Q2 2026
- Ishara Investments LP 55.35K sh · $2.43M · Q2 2026
More on M28 Capital Management LP
FAQ
How long has M28 Capital Management LP held SLN?
M28 Capital Management LP has disclosed SLN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.
What is M28 Capital Management LP's current position in SLN?
As of Q3 2026, M28 Capital Management LP holds 101.20K shares of SLN (SILENCE THERAPEUTICS PLC), valued at $1.11M, representing 3.07% of its reported portfolio and ranking #5.
Has M28 Capital Management LP been buying or selling SLN?
In the latest 13F filing (Q3 2026), M28 Capital Management LP held unchanged its position in SLN. The position peaked in Q1 2024 at 299.40K shares.
Which other funds hold SLN?
Other major institutional holders of SLN include TCG Crossover Management, LLC, Siren, L.L.C., Redmile Group, LLC, among 37 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.